Tumour lysis syndrome

Villas, J. M. Calvo

doi:10.1016/j.medcle.2019.03.006

Cited by 10 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In group A, 77.2% of patients were in the AH group, and 22.8% were in the non-AH group; in group B, 86.7% of patients were in the AH group, and 13.3% were in the non-AH group. A significant difference in sum of hospitalization days was found between the two groups in the patients with arterial hypertension (group A, 8 [ 6 , 7 , 8 , 9 , 10 , 11 ] vs. group B, 11 [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ]; p < 0.0001), as well as those without arterial hypertension (group A, 7 [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ] vs. group B, 12 [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ]; p = 0.003) ( Table 5 ; Figure 2 A,B).…”

Section: Resultsmentioning

confidence: 99%

“…Hyperkalemia, defined as a concentration of serum potassium > 5.1 mEq/L, can be due to (1) impaired excretion of potassium in urine owing to renal failure; (2) renin–angiotensin–aldosterone system inhibitors (RAASIs); drugs interfering with aldosterone metabolism and renin release (heparin or ketoconazole and nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclosporine) and with ion-channel function (β-blockers and digoxin in relation to the Na-K pump; amiloride, trimethoprim and pentamidine in relation to the Na channel); (3) shift from the intracellular compartment after intravenous infusion of glucose; (4) tumor lysis syndrome; (5) increased potassium intake, especially in patients with renal impairment [ 1 , 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of hyperkalemia increased from 2% to 42% if the estimated glomerular filtration rate (eGFR) decreased from 60 mL/min/1.73 m 2 to 20 mL/min/1.73 m 2 [ 11 , 12 ]. Moreover, age, male gender, heart failure (HF) with reduced ejection fraction and cancer are risk factors associated with hyperkalemia [ 6 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease

Calabrese

Cernaro

Battaglia

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: This observational study aimed to verify the association between serum potassium levels and hospitalization days in patients with chronic kidney disease in a follow up of nine months. (2) Methods: Patients with chronic kidney disease were divided into group A (180 patients, potassium ≤ 5.1 mEq/L) and B (90 patients, potassium > 5.1 mEq/L). Student’s t-test, Mann–Whitney test, Pearson’s Chi-Square test, Pearson/Spearman’s correlation test and linear regression test were performed in the entire sample and in stage-G4/5 subsample. (3) Results: Groups A and B differed for estimated glomerular filtration rate (eGFR) (34.89 (IQR, 16.24–57.98) vs. 19.8 (IQR, 10.50–32.50) mL/min/1.73 m2; p < 0.0001), hemoglobin (11.64 ± 2.20 vs. 10.97 ± 2.19 g/dL, p = 0.048), sum of hospitalization days (8 (IQR, 6–10) vs. 11 (IQR, 7–15) days; p < 0.0001) and use of angiotensin II receptor blockers (40.2% vs. 53.3%; p = 0.010). Considering patients with eGFR 6–30 mL/min/1.73 m2, differences in the sum of hospitalization days were confirmed. Multivariable regression analysis showed that hyperkalemia is an independent risk factor of increased hospital length. In stage G4-G5, regression analysis showed that hyperkalemia is the only independent risk factor (β = 2.93, 95% confidence interval, 0.077–5.794, p = 0.044). (4) Conclusions: We observed significantly greater odds of increased length of hospital stay among patients with higher potassium, mostly in stages G4–G5 chronic kidney disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease

Calabrese

Cernaro

Battaglia

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…The most dangerous drug-induced hyperuric acid is hyperuricemia caused by cytotoxic medicines ( 13 ). Hyperuricemia, which usually develops 48 to 72 h following cytotoxic drug treatment, can lead to tumor cytolysis syndrome (TLS), a life-threatening emergency, which should be avoided ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients

Wang¹,

Yang²,

Mei³

et al. 2021

Transl Breast Cancer Res

View full text Add to dashboard Cite

Background: High levels of serum uric acid (SUA)are associated with a poor survival rate of breast cancer.Meanwhile, a sharp increase in SUA after chemotherapy may lead to tumor lysis syndrome (TLS). We created and validated a nomogram to help doctors better manage the patient's SUA level ahead of time in this study. Methods: From July 2012 to June 2021, 206 patients with breast cancer undergoing chemotherapy participated in the study. They are randomly divided into training set (n=137) and validation set (n=69). Univariate and multivariate logistic regression analysis was used to screen the independent predictors of the risk of elevated uric acid in the whole training set data. The receiver operating characteristic (ROC) curve and decision curve assessed the accuracy and clinical application value of nomogram. Results: We confirmed that body mass index (BMI), age, menopause, EC-T chemotherapy (Epirubicin-Cyclophosphamide followed by Paclitaxel) and THP + C-T (Pirarubicin-Cyclophosphamide followed by Paclitaxel) are independent risk factors for high SUA. We established a nomogram for high SUA risk prediction to help clinicians make individualized choice of chemotherapy regimen. In the training cohort, the area under the ROC curve (AUC) showed statistical accuracy (AUC =0.796). Decision curve analysis proved the clinical value of the nomogram. Conclusions: This nomogram can be used to calculate the specific likelihood of high SUA in patients with breast cancer undergoing chemotherapy with different chemotherapy options.

show abstract

“…Tumor lysis syndrome (TLS) is a life-threatening catastrophe characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia [ 1 , 2 ]. These metabolic imbalances can result in acute kidney injury, cardiac arrhythmia, neurological sequela, and finally death owing to multiple organ failure.…”

Section: Introductionmentioning

confidence: 99%

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma

Yen

Chang

Shiu

2020

Case Rep Gastroenterol

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore, we present a case of a female patient with newly diagnosed advanced HCC who developed TLS and hepatic failure after receiving combination therapy of nivolumab and sorafenib. To our knowledge, this is the first case of TLS in a patient with advanced HCC owing to combination therapy of nivolumab and sorafenib. We also reviewed the literature and summarized the characteristics of TLS in patients with advanced HCC receiving various therapeutic interventions. The overall mortality rate was 63% and regarding the management, transarterial chemoembolization (TACE) was the most common etiology. TACE-related TLS developed more rapidly than sorafenib-related TLS. Furthermore, the efficacy and safety of combination therapy of nivolumab and sorafenib should be further evaluated, and TLS should still be a concern, especially in patients with large tumor burden.

show abstract

Tumour lysis syndrome

Cited by 10 publications

References 51 publications

Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease

Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease

The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma

Contact Info

Product

Resources

About